Fusix Biotech
- Home
- Companies
- Fusix Biotech
- Products
- FUSIX Technology
FUSIX Technology
FromFusix Biotech
The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This results in an oncolytic virus platform with an excellent safety profile and effective replication kinetics. Tumor-selective replication leads to significant oncolytic activity, while fusion-based cell death adds to its potent immune-stimulatory properties. Together this results in tumor regression and systemic tumor-specific immunity.
Most popular related searches
infect tumor cell
tumor immunity
tumor immune
immune checkpoints
immune tolerance
tumor specificity
immune checkpoint
immune cell
T-cell
cancer cell
Oncolytic viruses have been identified as highly promising candidates for combination immunotherapies, because of their potential to induce immune cell infiltration and breakdown of the tumor immune tolerance. Additionally, they activate a response against neoepitopes that are released by an immunogenic cell death of infected tumor cells. The FUSIX technology offers a potent and flexible platform for combination approaches with immune checkpoint inhibitors, as well as adoptive cell transfer, including T cells as well as dendritic cells.
